Product Images Gabapentin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Gabapentin NDC 68788-9509 by Preferred Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Gabapentin Capsules, USP 400mg

Gabapentin Capsules, USP 400mg

This text contains information about Gabapentin Capsules, USP 400mg, which is a medication used to treat seizures and nerve pain. The text also notes that the transfer of Gabapentin Capsules is prohibited by federal law without a prescription. The product is a generic version of Neurontin and is manufactured by Ascend Laboratories, LLC. Additionally, the text provides information about the capsule contents and packaging details.*

gabapentin-equation - gabapentin equation

gabapentin-equation - gabapentin equation

This appears to be a formula for calculating something related to medical information, possibly related to kidney function. The formula includes weight in kilograms, serum creatinine levels measured in mg/dL, and a multiplier specific to female patients. However, the quality of the text is poor and it is difficult to interpret certain characters, so the formula may not be accurate or complete.*

gabapentin fig1

gabapentin fig1

This is a chart showing the mean pain score for a 4-week dose titration period and a 4-week fixed dose period. The baseline score is not available. The chart compares the effects of a placebo with Gabapentin at a dosage of 3600mg/day.*

gabapentin fig2

gabapentin fig2

This appears to be a chart or graph showing mean pain score data over different periods for a study involving a placebo and different doses of gabapentin. The chart includes baseline data and different weeks of the study.*

gabapentin fig3

gabapentin fig3

The text is a table showing the percentage of responders at endpoint in controlled PHN studies. It includes the percentage of patients who had a 50% reduction in pain score and the different treatments used in the studies (GBP 3600, PBO, GEBP 1800, and GBP 2400). There is also a note indicating that "#p<00l< 0,001" (presumably indicating a statistically significant difference between groups) but no further details are available.*

gabapentin-fig4 - gabapentin fig4

gabapentin-fig4 - gabapentin fig4

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.